UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.usplo.gov

#### NOTICE OF ALLOWANCE AND FEE(S) DUE

7278 7590

01/25/2010

DARBY & DARBY P.C. P.O. BOX 770 Church Street Station New York, NY 10008-0770 EXAMINER
WANG, CHANG YU

PAPER NUMBER

ART UNIT 1649 DATE MAILED: 01/25/2010

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNICY DOCKET NO.
 CONFIRMATION NO.

 10/561/015
 02/17/2006
 Dan P. Felsenfeld
 02/420/100M761-US1
 9430

TITLE OF INVENTION: PEPTIDES FOR TREATING AXONAL DAMAGE, INHIBITION OF NEUROTRANSMITTER RELEASE AND PAIN TRANSMISSION, AND BLOCKING CALCIUM INFLUX IN NEURONS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	04/26/2010

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT, PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 1SI. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FIEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

## PART B - FEE(S) TRANSMITTAL

# Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where

appropriate. All further correspondence including the Patent, advance orders and notification indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new of maintenance fee notifications.  CURRENT CORRESPONDENCE ADDRESS (Noze: the Block 1 for any change of address)				Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.			
DARBY & DAP P.O. BOX 770 Church Street St	ation	/2010		Cert	ificate	of Mailing or Trans	nission deposited with the United t class mail in an envelope above, or being facsimile tte indicated below.
New York, NY	10008-0770						(Depositor's name)
							(Signature)
							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.
		REATING AXONAL I MINFLUX IN NEURON	Dan P. Felsenfeld DAMAGE, INHIBITION S	OF NEUROTRAN		20/100M761-US1 FTER RELEASE AN	9430 D PAIN
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0		\$1810	04/26/2010
EXAM	INER	ART UNIT	CLASS-SUBCLASS	1			
WANG, CI	HANG YU	I649	530-300000	•			
"Fee Address" ind PTO/SB/47; Rev 03-0 Number is required.  3. ASSIGNEE NAME A	ND RESIDENCE DATA	" Indication form ed. Use of a Customer A TO BE PRINTED ON	(I) the names of up to or agents OR, alternati- (2) the name of a singl registered attorney or a 2 registered patent atto listed, no name will be THE PATENT (print or typ- data will appear on the p (T a substitute for filing an	vely, e firm (having as a agent) and the name meys or agents. If n printed.	memb s of u so nam	p to a se is 3	ocument has been filed for
4a. The following fee(s)	iate assignee category or are submitted: To small entity discount p	41	(B) RESIDENCE: (CITY  inted on the patent):   b. Payment of Fee(s): (Plea  A check is enclosed.  Payment by credit car  The Director is hereby overpayment, to Depo	Individual Coruse first reapply and	rporati y prev is atta	ion or other private gro viously paid issue fee s sched.	
	s SMALL ENTITY state	is. See 37 CFR I.27.	b. Applicant is no lon				R 1.27(g)(2). e assignee or other party in
Authorized Signature							
Typed or printed name		Registration No.					
This collection of inform an application. Confiden submitting the complete this form and/or suggests Box 1450, Alexandria, V Alexandria, Virginia 223	ation is required by 37 C tiality is governed by 35 d application form to the ons for reducing this bu (irginia 22313-1450. DC (13-1450.	FR 1.311. The informatis U.S.C. 122 and 37 CFR USPTO. Time will vary den, should be sent to th ONOT SEND FEES OR	on is required to obtain or r 1.14. This collection is est r depending upon the indiv e Chief Information Office COMPLETED FORMS TO	retain a benefit by th timated to take 12 nr idual case. Any cor er, U.S. Patent and 7 D THIS ADDRESS.	ne publ ninutes mment Fraden SENI	lic which is to file (and s to complete, including its on the amount of tin nark Office, U.S. Depa D TO: Commissioner f	by the USPTO to process) g gathering, preparing, and ne you require to complete atment of Commerce, P.O. for Patents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

#### UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/561,015	02/17/2006		Dan P. Felsenfeld	02420/100M761-US1	9430
7278	7590	01/25/2010		EXAM	UNER
DARBY & DARBY P.C.			WANG, CHANG YU		
P.O. BOX 770				ART UNIT	PAPER NUMBER
Church Street St New York, NY 1				1649 DATE MAII ED: 01/25/201	0

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 176 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 176 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

# Notice of Allowability

Application No.	Applicant(s)
10/561,015	FELSENFELD ET AL.
Examiner	Art Unit
CHANG-YU WANG	1649

The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included					
herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS					
NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative					
of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.					
4 N This					

to file Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
. X This communication is responsive to a conversation with the attorney of record on 1/8/10 after an advisory action mailed 1/5/10.
2. ☑ The allowed claim(s) is/are <u>1.6.7,18,20,23 and 24.</u>
B. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of the:
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>
<ol><li>Certified copies of the priority documents have been received in Application No</li></ol>
3. Copies of the certified copies of the priority documents have been received in this national stage application from the
International Bureau (PCT Rule 17.2(a)).
* Certified copies not received:
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

international bareau (i of rate 17.2(a)).
* Certified copies not received:
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached  1) ☐ hereto or 2) ☐ to Paper No./Mail Date
<ul> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> </ul>
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
DEPOSIT OF A AMERICAN A AMERICAN ASSESSMENT OF A STATE

DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)	_
I. Notice of References Cited (PTO-892)	<ol><li>Notice of Informal Patent Application</li></ol>
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary (PTO-413), Paper No./Mail Date
B. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. X Examiner's Amendment/Comment
I. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Statement of Reasons for Allowance
•	9. Other
/C. Y. W./	/Christine J Saoud/
Examiner, Art Unit 1649	Primary Examiner, Art Unit 1647

Application/Control Number: 10/561,015

Art Unit: 1649

Claims 6-7, 19-20 and 23-24 were amended in the response filed 18 December 2009. Claims 1, 6-7, and 18-24 are currently pending and the subject of the instant Office action.

## EXAMINER'S AMENDMENT

 An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Irina E. Vainberg on January 11, 2010 and January 12, 2010.

The application has been amended as follows:

#### In the claims:

Please cancel claims 19 and 21-22 without prejudice.

6. (Currently Amended) An isolated peptide derived from the ankyrin binding domain of an L1-CAM family member protein, wherein said peptide (i) does not contain transmembrane and extracellular portions of the L1-CAM family member protein, (ii) comprisesing thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2), and , wherein said peptide (iii) promotes neurite outgrowth.

Application/Control Number: 10/561,015

Art Unit: 1649

- 7. (Currently Amended) The peptide of claim 6 comprising thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2) linked to thean amino acid sequence of RQIKIWFQNRRMKWKK (SEQ ID NO: 6), wherein said sequences are linked by a disulfide bond.
- 20. (Currently Amended) An isolated The peptide of claim 19 consisting of thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2).
- 23. (Currently Amended) The peptide of claim 22-6, wherein the which comprises a targeting sequence comprisesing the amino acid sequence of RQIKIWFQNRRMKWKK (SEQ ID NO: 6).
- 24. (Currently Amended) An isolated The peptide of claim 23 consisting of thean amino acid sequence of RQIKIWFQNRRMKWKKQFNEDGSFIGQF (SEQ ID NO: 3).

# Rejoinder

2. Claims 6-7, 18, 20, 23 and 24 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claim 1, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 4/3/08 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim

presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

- 3. Claims 1, 6-7 18, 20 and 23-24 are allowed. Claims 6-7, 18, 20, 23 and 24 were renumbered as claims 1-6 and claim 1 was renumbered as claim 7.
- 4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chang-Yu Wang whose telephone number is 571-272-4521. The examiner can normally be reached on Monday through Thursday 8:00am to 6:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker, can be reached on 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Application/Control Number: 10/561,015 Page 5

Art Unit: 1649

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Christine J Saoud/ Primary Examiner, Art Unit 1647

/CYW/ Chang-Yu Wang, Ph.D. January 12, 2010